Go Pro
→ Silicon Valley Insider: 'Forget AI Stocks' (From Brownstone Research) (Ad)tc pixel Free NEUP Stock Alerts

Neuphoria Therapeutics (NEUP) Competitors

Neuphoria Therapeutics logo
$3.95 +0.04 (+1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$3.93 -0.02 (-0.51%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NEUP vs. ACRV, OKYO, ACET, SERA, and TELO

Should you buy Neuphoria Therapeutics stock or one of its competitors? Neuphoria Therapeutics's main competitors and comparable companies include Acrivon Therapeutics (ACRV), OKYO Pharma (OKYO), Adicet Bio (ACET), Sera Prognostics (SERA), and Telomir Pharmaceuticals (TELO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neuphoria Therapeutics compare to Acrivon Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Neuphoria Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$15.65M1.36-$370K-$11.06N/A
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A

In the previous week, Acrivon Therapeutics had 4 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 0 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.00 beat Acrivon Therapeutics' score of -0.25 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Neuphoria Therapeutics Neutral
Acrivon Therapeutics Neutral

Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Acrivon Therapeutics' return on equity of -70.14% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -76.93% -54.76%
Acrivon Therapeutics N/A -70.14%-61.60%

Neuphoria Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 431.65%. Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 513.64%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Neuphoria Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Acrivon Therapeutics beats Neuphoria Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to OKYO Pharma?

Neuphoria Therapeutics (NASDAQ:NEUP) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Neuphoria Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 431.65%. OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 277.78%. Given Neuphoria Therapeutics' higher possible upside, equities analysts clearly believe Neuphoria Therapeutics is more favorable than OKYO Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
OKYO Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Neuphoria Therapeutics has higher revenue and earnings than OKYO Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$15.65M1.36-$370K-$11.06N/A
OKYO PharmaN/AN/A-$8.95MN/AN/A

Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

In the previous week, OKYO Pharma had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 1 mentions for OKYO Pharma and 0 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.

Company Overall Sentiment
Neuphoria Therapeutics Neutral
OKYO Pharma Neutral

OKYO Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -76.93% -54.76%
OKYO Pharma N/A N/A N/A

Summary

OKYO Pharma beats Neuphoria Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Adicet Bio?

Adicet Bio (NASDAQ:ACET) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, Adicet Bio had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 1 mentions for Adicet Bio and 0 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.00 beat Adicet Bio's score of -1.00 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Adicet Bio Negative
Neuphoria Therapeutics Neutral

Adicet Bio currently has a consensus price target of $46.80, indicating a potential upside of 425.84%. Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 431.65%. Given Neuphoria Therapeutics' higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Adicet Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adicet Bio
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Adicet Bio's return on equity of -74.90% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Adicet BioN/A -74.90% -60.87%
Neuphoria Therapeutics N/A -76.93%-54.76%

Neuphoria Therapeutics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adicet BioN/AN/A-$116.80M-$11.45N/A
Neuphoria Therapeutics$15.65M1.36-$370K-$11.06N/A

83.9% of Adicet Bio shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 3.4% of Adicet Bio shares are owned by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Adicet Bio has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Summary

Adicet Bio beats Neuphoria Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Sera Prognostics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 431.65%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 152.29%. Given Neuphoria Therapeutics' higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Sera Prognostics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sera Prognostics had 4 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 4 mentions for Sera Prognostics and 0 mentions for Neuphoria Therapeutics. Sera Prognostics' average media sentiment score of 0.24 beat Neuphoria Therapeutics' score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company Overall Sentiment
Neuphoria Therapeutics Neutral
Sera Prognostics Neutral

Neuphoria Therapeutics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$15.65M1.36-$370K-$11.06N/A
Sera Prognostics$80K1,075.01-$31.93M-$0.67N/A

Neuphoria Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -76.93% -54.76%
Sera Prognostics -47,475.72%-46.71%-34.06%

Summary

Sera Prognostics beats Neuphoria Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Telomir Pharmaceuticals?

Neuphoria Therapeutics (NASDAQ:NEUP) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Neuphoria Therapeutics Neutral
Telomir Pharmaceuticals Neutral

Neuphoria Therapeutics presently has a consensus target price of $21.00, suggesting a potential upside of 431.65%. Given Neuphoria Therapeutics' higher possible upside, equities analysts clearly believe Neuphoria Therapeutics is more favorable than Telomir Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Neuphoria Therapeutics' return on equity of -76.93% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -76.93% -54.76%
Telomir Pharmaceuticals N/A -102.70%-90.75%

Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

Neuphoria Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$15.65M1.36-$370K-$11.06N/A
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.91N/A

Summary

Neuphoria Therapeutics beats Telomir Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

Get Neuphoria Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NEUP vs. The Competition

Export
MetricNeuphoria TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$21.33M$3.99B$7.29B$12.71B
Dividend YieldN/A3.64%2.54%10.79%
P/E Ratio-0.3611.75271.3824.10
Price / Sales1.361,398.77638.9590.12
Price / Cash25.0944.9429.0336.90
Price / Book0.3917.2611.186.40
Net Income-$370K-$22.72M$3.46B$348.28M
7 Day Performance2.60%2.89%1.98%0.91%
1 Month Performance8.52%9.74%7.32%5.10%
1 Year Performance-44.99%54.81%24.76%16.16%

Neuphoria Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NEUP
Neuphoria Therapeutics
2.2773 of 5 stars		$3.95
+1.0%		$21.00
+431.6%		-45.5%$21.33M$15.65MN/AN/A
ACRV
Acrivon Therapeutics
3.4516 of 5 stars		$1.95
+5.4%		$13.50
+592.3%		+62.5%$83.46MN/AN/A58
OKYO
OKYO Pharma
1.6551 of 5 stars		$1.52
+0.7%		$5.67
+272.8%		-35.0%$79.77MN/AN/A7
ACET
Adicet Bio
2.5286 of 5 stars		$8.38
+1.5%		$46.80
+458.5%		-21.0%$78.45MN/AN/A90
SERA
Sera Prognostics
2.9365 of 5 stars		$1.96
-2.5%		$5.50
+180.6%		-10.1%$76.75M$80KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NEUP) was last updated on 8/24/2026 by MarketBeat.com Staff.
From Our Partners
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel